Mediar Therapeutics

About:

Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.

Top Investors: Mission BioCapital, Bristol-Myers Squibb, Eli Lilly & Company Foundation, Novartis Venture Fund, Sofinnova Partners

Description:

Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis. Its therapeutics target key fibrotic mediator proteins that aid in the development of fibrosis in chronically-damaged organs. The company was founded in 2019 and is headquartered in Cambridge, Massachusetts.

Total Funding Amount:

$105M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2018-01-01

Founders:

Meredith Fisher, Paul Yaworsky

Number of Employees:

11-50

Last Funding Date:

2023-03-15

IPO Status:

Private

Industries: